tirzepatide api | DMFs Tirzepatide API Manufacturers | Suppliers

Personalized medicine is one of the primary promises of telehealth, so when patients feel their treatment lacks individualization, it undermines the entire value proposition

Tirzepatide, a dual GIP/GLP-1 agonist, showed up to 20.9% average weight loss in SURMOUNT-1 at 72 weeks

Shown to reduce symptoms by up to 69% in studies

This place ROCKS

And I think that's something we're hopefully trying to start to shift

While GLP-1 therapies may reduce long-term risks of cardiovascular disease, diabetes complications, and disability, those benefits often accrue over decadeswell beyond the timeframe relevant to most employer plan sponsors